Join Growin Stock Community!
Back to ABBV.US Analysis
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

revenue-breakdown-chart

ABBV Revenue by Segments

Revenue by Segments

Browsing restrictions can be lifted for a fee.

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q3'25, ABBV's total revenue is primarily driven by the Immunology segment at 7.89B USD, followed by Oncology at 1.68B USD, Neuroscience at 2.84B USD, Aesthetics at 1.19B USD, and Other Key Products contributing 1.64B USD. Immunology remains the dominant segment, accounting for the largest share of quarterly revenue in the latest period. From Q4'22 to Q3'25, the chart reveals that Immunology consistently leads ABBV's revenue mix, though it exhibits some quarterly fluctuations, peaking at 9.01B USD in Q4'23. Oncology and Aesthetics show relatively stable contributions, while Neuroscience displays more volatility, with a notable spike to 4.41B USD in Q4'24. Overall, the revenue distribution highlights Immunology's sustained dominance, with Neuroscience emerging as a significant growth area in recent quarters.